Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan

World J Gastroenterol. 2015 Oct 7;21(37):10669-74. doi: 10.3748/wjg.v21.i37.10669.

Abstract

Aim: To determine changes in the antibiotic resistance of Helicobacter pylori (H. pylori) in southern Taiwan after failure of first-line standard triple therapy.

Methods: We analyzed 137 H. pylori-infected isolates from patients who experienced eradication failure after standard first-line triple therapy from January 2010 to December 2014. The H. pylori strains were tested for susceptibility to amoxicillin, clarithromycin, levofloxacin, metronidazole and tetracycline using the E-test method. The minimal inhibitory concentration (MIC) was determined by the agar dilution test. MIC values of ≥ 0.5, ≥ 1, ≥ 1, ≥ 4 and ≥ 8 mg/L were considered to be the resistance breakpoints for amoxicillin, clarithromycin, levofloxacin, tetracycline and metronidazole, respectively.

Results: A high resistance rate was found for clarithromycin (65%-75%) and metronidazole (30%-40%) among patients who failed first-line standard therapy. The resistance levels to amoxicillin and tetracycline remained very low; however, levofloxacin resistance was as high as 37.5% in 2010 but did not increase any further during the past 5 years. The rates of resistance to these antibiotics did not show a statistically significant upward or downward trend.

Conclusion: Antibiotic resistance of H. pylori remains a problem for the effective eradication of this pathogen and its associated diseases in Taiwan. High clarithromycin resistance indicated that this antibiotic should not be prescribed as a second-line H. pylori eradication therapy. Moreover, levofloxacin-based second-line therapy should be used cautiously, and the local resistance rates should be carefully monitored.

Keywords: Antibiotic resistance; Failed first-line therapy; Five-year sequential changes; Helicobacter pylori; Southern Taiwan.

MeSH terms

  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use*
  • Biopsy
  • Clarithromycin / therapeutic use
  • Drug Resistance, Bacterial
  • Drug Resistance, Microbial*
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / microbiology*
  • Helicobacter pylori / drug effects*
  • Humans
  • Levofloxacin / therapeutic use
  • Metronidazole / therapeutic use
  • Microbial Sensitivity Tests
  • Retrospective Studies
  • Taiwan
  • Tetracycline / therapeutic use
  • Time Factors

Substances

  • Anti-Bacterial Agents
  • Metronidazole
  • Levofloxacin
  • Amoxicillin
  • Tetracycline
  • Clarithromycin